Bradley Canino
Stock Analyst at Guggenheim
(4.31)
# 1,296
Out of 4,455 analysts
295
Total ratings
45.6%
Success rate
10.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DMRA Damora Therapeutics | Maintained: Buy | $40 | $25.36 | +57.73% | 5 | Jun 15, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintained: Buy | $34 → $31 | $21.31 | +45.47% | 17 | Jun 12, 2026 | |
| NUVL Nuvalent | Downgraded: Hold | $151 → $124 | $123.52 | +0.39% | 16 | Jun 9, 2026 | |
| CELC Celcuity | Maintained: Buy | $165 | $99.95 | +65.08% | 14 | Jun 3, 2026 | |
| SMMT Summit Therapeutics | Maintained: Buy | $40 | $14.01 | +185.51% | 15 | Jun 1, 2026 | |
| OLMA Olema Pharmaceuticals | Maintained: Buy | $38 → $35 | $11.39 | +207.29% | 5 | Jun 1, 2026 | |
| BCAX Bicara Therapeutics | Maintained: Buy | $42 | $26.87 | +56.31% | 2 | May 26, 2026 | |
| RLAY Relay Therapeutics | Maintained: Buy | $22 → $26 | $18.56 | +40.09% | 18 | May 25, 2026 | |
| JANX Janux Therapeutics | Reiterated: Buy | $68 → $58 | $14.94 | +288.22% | 9 | May 7, 2026 | |
| ORIC ORIC Pharmaceuticals | Reiterated: Buy | $18 | $9.53 | +88.88% | 9 | May 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $125 | $108.12 | +15.61% | 20 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 | $18.56 | +88.58% | 3 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $54 | $31.88 | +69.39% | 1 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $18.40 | +63.04% | 7 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $90 | $71.96 | +25.07% | 3 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $7 | $4.26 | +64.32% | 20 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.71 | - | 17 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $10.90 | - | 21 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 → $5 | $2.77 | +80.51% | 5 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 | $4.04 | n/a | 23 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $3 → $1.5 | $2.04 | n/a | 20 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $63 → $51 | $8.00 | n/a | 25 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0001 | n/a | 13 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $37 | $4.81 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $65 | $54.76 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $68 | $3.68 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $5.92 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $54.77 | n/a | 1 | Mar 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $55 | $24.15 | n/a | 1 | Mar 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $38 | $26.74 | n/a | 1 | Jul 8, 2020 |
Damora Therapeutics
Jun 15, 2026
Maintained: Buy
Price Target: $40
Current: $25.36
Upside: +57.73%
Syndax Pharmaceuticals
Jun 12, 2026
Maintained: Buy
Price Target: $34 → $31
Current: $21.31
Upside: +45.47%
Nuvalent
Jun 9, 2026
Downgraded: Hold
Price Target: $151 → $124
Current: $123.52
Upside: +0.39%
Celcuity
Jun 3, 2026
Maintained: Buy
Price Target: $165
Current: $99.95
Upside: +65.08%
Summit Therapeutics
Jun 1, 2026
Maintained: Buy
Price Target: $40
Current: $14.01
Upside: +185.51%
Olema Pharmaceuticals
Jun 1, 2026
Maintained: Buy
Price Target: $38 → $35
Current: $11.39
Upside: +207.29%
Bicara Therapeutics
May 26, 2026
Maintained: Buy
Price Target: $42
Current: $26.87
Upside: +56.31%
Relay Therapeutics
May 25, 2026
Maintained: Buy
Price Target: $22 → $26
Current: $18.56
Upside: +40.09%
Janux Therapeutics
May 7, 2026
Reiterated: Buy
Price Target: $68 → $58
Current: $14.94
Upside: +288.22%
ORIC Pharmaceuticals
May 4, 2026
Reiterated: Buy
Price Target: $18
Current: $9.53
Upside: +88.88%
Apr 30, 2026
Reiterated: Buy
Price Target: $125
Current: $108.12
Upside: +15.61%
Apr 29, 2026
Maintained: Buy
Price Target: $35
Current: $18.56
Upside: +88.58%
Apr 15, 2026
Initiated Coverage: Buy
Price Target: $54
Current: $31.88
Upside: +69.39%
Mar 10, 2026
Reiterated: Buy
Price Target: $30
Current: $18.40
Upside: +63.04%
Feb 27, 2026
Reiterated: Buy
Price Target: $90
Current: $71.96
Upside: +25.07%
Feb 26, 2026
Reiterated: Buy
Price Target: $8 → $7
Current: $4.26
Upside: +64.32%
Dec 3, 2025
Downgraded: Hold
Price Target: n/a
Current: $1.71
Upside: -
Sep 3, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $10.90
Upside: -
Sep 3, 2025
Initiated Coverage: Buy
Price Target: $10 → $5
Current: $2.77
Upside: +80.51%
Mar 27, 2025
Maintained: Buy
Price Target: $9
Current: $4.04
Upside: n/a
Mar 7, 2025
Maintained: Hold
Price Target: $3 → $1.5
Current: $2.04
Upside: n/a
Feb 12, 2025
Maintained: Buy
Price Target: $63 → $51
Current: $8.00
Upside: n/a
Jan 9, 2025
Rated: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $37
Current: $4.81
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $65
Current: $54.76
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $68
Current: $3.68
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $30
Current: $5.92
Upside: n/a
Mar 30, 2021
Initiated Coverage: Buy
Price Target: $30
Current: $54.77
Upside: n/a
Mar 30, 2021
Initiated Coverage: Buy
Price Target: $55
Current: $24.15
Upside: n/a
Jul 8, 2020
Initiated Coverage: Buy
Price Target: $38
Current: $26.74
Upside: n/a